Zembrace® SymTouch® is indicated for the acute treatment of migraine with or without aura in adults.
Limitations of Use: Use only if a clear diagnosis of migraine has been established. Not indicated for the preventive treatment of migraine.
Zembrace® SymTouch® is contraindicated in patients with a history of hemiplegic or basilar migraine. This is not the only contraindication for Zembrace® SymTouch®.
Please see complete Important Safety Information and full Prescribing Information.
Different treatment for different patients
When to prescribe
Zembrace® SymTouch®
for as little as $0*
The Access Pathways® Program is a best-in-class savings and support program. Access Pathways®, in partnership with BlinkRx, offers:


Fast, free home delivery

Dedicated customer support to guide you and your patients through the process
Want more information?
Sign up today to learn more about Zembrace® SymTouch®.
References:
- Zembrace SymTouch [package insert]. Maple Grove, MN: Upsher-Smith Laboratories, LLC: February 2021.
- Mathew NT, et al. Dose ranging efficacy and safety of subcutaneous sumatriptan in the acute treatment of migraine. US Sumatriptan Research Group. Arch Neurol. 1992;49(12):1271-1276